FDA Clears DeepHealth's AI Breast Suite for Cardiovascular Insights, Enhanced Cancer Detection
RDNT is trading near its 52-week low of $50.76 (15% above the low).
Summary
DeepHealth, a wholly owned subsidiary of RadNet, received two FDA 510(k) clearances for its AI-powered Breast Suite. These clearances enable new functionalities: Breast Arterial Calcification (BAC) Assessment for cardiovascular insights and Mammo Dx for prior exam integration to improve cancer detection and reduce recalls. These commercially available enhancements strengthen RadNet's Digital Health segment by offering more comprehensive and competitive tools for radiologists. This development aligns with the company's recent strong financial performance and strategic growth initiatives.
At the time of this announcement, RDNT was trading at $58.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $50.76 to $85.84. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.